HB420 updates Maryland law governing access to and use of epinephrine for emergency treatment of anaphylaxis. The bill replaces the term “auto-injectable epinephrine” with “emergency use epinephrine” across multiple education, health, and health occupations provisions, and broadens the definition to include certain FDA-approved drug delivery devices or products beyond traditional auto-injectors. It also renames the “Emergency Use Auto-Injectable Epinephrine Program” as the “Emergency Use Epinephrine Program.”
The bill preserves and restates existing authority for public schools, nonpublic schools, child care settings, youth camps, and certain higher-education food service or recreation facilities to obtain, store, and administer epinephrine in emergencies when anaphylaxis is suspected and medical help is not immediately available. It continues existing requirements for staff training, parent notification, incident reporting, and civil liability protections for good-faith responders, while updating terminology throughout the affected statutes. The bill also maintains the role of physicians, nurse practitioners, pharmacists, and designated certificate holders in prescribing, dispensing, storing, and administering the medication, and it keeps the naturopathic medicine formulary provisions aligned with the updated term.
In practical terms, the bill modernizes state law to match current FDA terminology and product types, while leaving the underlying emergency-response framework largely intact. It affects the Education Article, Health–General Article, and Health Occupations Article, but does not create a new program so much as revise and rename existing ones. Schools, child care providers, youth camps, participating facilities, and licensed health professionals are the primary parties affected.
The overall sentiment reflected in the voting history was strongly supportive and noncontroversial. The bill passed the House 137-0 and the Senate 46-0, indicating unanimous approval in both chambers. No committee transcript concerns were provided, and the unanimous votes suggest broad agreement that the changes were technical, clarifying, and safety-oriented.
There is little evidence of substantive contention in the available record. The main policy issue is the terminology change and expansion of the definition to include additional FDA-approved epinephrine delivery products, but the bill does not appear to have generated opposition. Any potential concern would likely center on implementation details—such as training, storage, and ensuring that newly covered products are treated consistently under existing emergency-use protocols—rather than on the bill’s overall purpose.
HB420 amends multiple sections of the Education Article, Health–General Article, and Health Occupations Article to replace references to “auto-injectable epinephrine” with “emergency use epinephrine” and to expand the definition to include certain FDA-approved drug delivery devices or products. It renames the state’s epinephrine program accordingly and updates related provisions on school policies, child care immunity, youth camp certification, facility participation, reporting requirements, and naturopathic prescribing authority. The bill largely preserves existing duties and protections while modernizing statutory language and broadening the types of epinephrine products covered.
The bill appears to have been viewed favorably and as largely technical or clarifying. It passed both chambers unanimously, with a 137-0 vote in the House and a 46-0 vote in the Senate. The absence of recorded committee testimony or dissent suggests broad bipartisan support and little controversy.
No notable opposition is reflected in the available materials. The only potentially debatable issue is the shift from a narrow “auto-injectable” definition to the broader “emergency use epinephrine” definition, which could affect how schools, camps, child care providers, and participating facilities select and store products. However, the unanimous votes indicate that any such concerns were not significant enough to generate recorded resistance.